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In this prospective, open-label, randomized, controlled
clinical trial the effects of low-dose carvedilol, nebivolol,
and metoprolol on central arterial pressure and augmenta-
tion index (AIx) and its heart rate–corrected value (AIx@75)
were assessed. The authors randomized 75 hypertensive
patients (18–70 years) to carvedilol 12.5/25 mg, metoprolol
50/100 mg, or nebivolol 2.5/5 mg daily and followed them
up for 3 months. Central arterial pressure and AIx were
measured with applanation tonometry at baseline and at the
end of follow-up. Analyses were restricted to 60 completers.
Central systolic pressure decreased equally in all 3 treatment
arms. AIx remained unchanged, while AIx@75 decreased
significantly by 5.4%2.5% in the nebivolol group. Accord-
ing to general linear models, individual change in heart rate
was a strong predictor of change in AIx in the carvedilol
group (r2=0.23, P=.03) although no similar association was
found in the nebivolol group (r2=0.09). The impact of
b-blockers with vasodilator effects on pressure augmenta-
tion seems to be different with nebivolol having the largest
potential of decreasing AIx@75. While AIx changes associ-
ated with carvedilol treatment are strongly driven by heart
rate changes, those associated with nebivolol treatment
seem to be the result of other mechanisms. J Clin Hypertens
(Greenwich). 2013;15:910–917. ª2013 Wiley Periodicals, Inc.
In the past decade, increasing attention has been drawn
to the unfavorable effects of b-blockers on central
hemodynamics. It is assumed that bradycardia elicited
by b-blockers results in slower development of the
forward-traveling wave and allows the reflected wave—
the energy of which is increased due to peripheral
vasoconstriction—to arrive during systole. The ensuing
interference of the forward-traveling and reflected waves
augments systolic pressure in the large arteries, thereby
diminishing the potential of central blood pressure (BP)
reduction.1 Indeed, many studies have found that at the
same level of peripheral pressure reduction, b-blockers
have a smaller effect on central BP compared with other
types of antihypertensive agents.2–4 According to the
Conduit Artery Function Evaluation (CAFE) study, a
smaller decrease in central BP may be a plausible
mechanism for the reduced effectiveness of b-blockers
in the prevention of cardiovascular events.5
b-Blockers, however, cannot be considered a homog-
enous group. Unfavorable hemodynamic effects and
clinical outcomes were demonstrated for atenolol, a
drug selected for the treatment of hypertension with
decreasing frequency.6 Newer b-blockers, such as carv-
edilol and nebivolol, may elicit smaller wave reflection
as a result of their vasodilatory effects. In older people
with isolated systolic hypertension, both atenolol and
nebivolol increased augmentation index (AIx), with the
latter evoking a smaller rise.7 In younger populations
with essential hypertension, heart rate-corrected AIx
(AIx@75) decreased in nebivolol-treated groups, but
not in groups receiving atenolol8 or metoprolol.9
Carvedilol treatment was also associated with smaller
central augmented pressure10 and a larger decrease in
AIx11 compared with metoprolol treatment. To our
knowledge, however, no randomized trials have com-
pared the effect of both vasodilator b-blockers (carv-
edilol and nebivolol) with a nonvasodilator b-blocker
(such as metoprolol) on central BP and its determinants.
In the current parallel-group, randomized, controlled
trial, our primary objective was to assess the effects of
low-dose carvedilol, nebivolol, and metoprolol on cen-
tral arterial pressure, AIx, and AIx@75. We hypothe-
sized that carvedilol and nebivolol would decrease
central arterial pressure more and increase AIx and
AIx@75 less than metoprolol. As a secondary objective,
we studied the effects of the above b-blockers on forward
and reflected pressure wave amplitude, pulse pressure
amplification, and carotid-femoral pulse wave velocity
(PWV). We also investigated how changes in heart rate
influence changes in AIx for each drug. Owing to their
vasodilatory effects, we expected to observe some heart
rate–independent effects of carvedilol and nebivolol.
METHODS
This was a prospective, open-label, 1:1:1, parallel-
group, randomized, controlled clinical trial with blinded
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endpoint evaluation comparing the effects of 3-month
treatment with carvedilol, nebivolol, and metoprolol on
central hemodynamics.
Study Population
b-Blocker-na€ıve, treated, or untreated hypertensive
patients (18–70 years) with uncontrolled hypertension
were recruited at the 1st Department of Medicine,
Semmelweis University and from local general practices.
Uncontrolled hypertension was defined as seated office
systolic and/or diastolic BP ≥140/90 mm Hg calculated
from the average of the second and the third readings of
3 consecutive measurements. For patients with diabetes
mellitus or chronic kidney disease (estimated glomerular
filtration rate ≤60 mL/min/1.73 m2), a cutoff value of
130/80 mm Hg was used. Patients with severe hyper-
tension (BP ≥180/110 mm Hg), atrial fibrillation, or
contraindications for b-blocker use were excluded. The
study was approved by the National Institute of
Pharmacy and by the ethics committee of the Hungarian
Medical Research Council and was registered at EUD-
RACT (2008-001509-40). All patients gave written
informed consent prior to participation.
Randomization
After screening eligibility for enrollment, patients were
randomly assigned to receive one of the following 3
antihypertensive agents for the following 3-month
period: carvedilol 12.5 mg daily, metoprolol succinate
50 mg daily, or nebivolol 2.5 mg daily. For treated
patients, trial medication was added on top of their
unaltered background medication. Randomization was
performed in blocks of 6. Investigators were blinded to
randomization; at patient enrollment, they called the
study center and received the next available treatment
allocation. Patients and investigators responsible for
enrollment and treatment were not blinded to treatment
assignment; however, investigators analyzing outcome
variables were blinded to treatment assignment and to
the sequence of measurements.
Protocol
After enrollment, baseline clinical, hemodynamic, and
laboratory data were obtained. At 1 month, drug side
effects were evaluated and office BP was measured. In
patients whose office BP was still in the hypertensive
range, the dose of the study drug was doubled. At the
end of the 3-month treatment period, hemodynamic and
laboratory measurements were repeated. All hemody-
namic measurements were made in the morning,
(2–3 hours after taking the morning dose of trial
medication).
Hemodynamic Measurements
At each visit, office BP and heart rate were measured in
triplicate by trained personnel after a 5-minute rest in a
seated position. Patients then received an ambulatory BP
monitoring (ABPM) device (ABPM-04, TensioMed,
Budapest, Hungary)12 that measured BP in regular
intervals (every 15 minutes during the day, every
30 minutes at night) for a 24-hour period. The follow-
ing morning, after the ABPM device had been taken off,
central BP measurements were performed. After
10 minutes of supine rest, 3-3 sequences of carotid
and femoral pulse waves, each containing 10 to 15 pulse
contours were recorded with a validated PulsePen
tonometer (DiaTecne srl, Milan, Italy)13 by well-trained
personnel. Carotid pulse waves were calibrated with
diastolic and mean brachial arterial pressures obtained
from an OMRON M4-I oscillometric device (OMRON
Matsusaka Co Ltd, Matsusaka City, Japan) after each
sequence of measurement.14 Mean arterial pressure was
calculated as diastolic pressure + pulse pressure/3. AIx
was defined as the difference between the second and
first peak or shoulder of the central arterial waveform,
expressed as a percentage of the pulse pressure.15 The
location of shoulders was estimated by the PulsePen
software using the fourth derivative of the raw pressure
curve.16,17 Pulse pressure amplification (AP) was calcu-
lated as brachial pulse pressure/central pulse pressure.
Pulse wave travel distance was assessed as the difference
between suprasternal notch-to-carotid site and supra-
sternal notch-to-femoral site obtained by surface tape
measurements. Dividing this path length with the
corresponding pulse transit time resulted in PWV
values.15 Forward-traveling and reflected pressure wave
amplitudes were determined using the triangulation
flow method. Details of the waveform decomposition
method have been described elsewhere.18,19 In all
patients, the average of 2 or 3 sets of measurements
were used in the calculations, depending on the quality
of the recorded pressure curves.
Laboratory Measurements
Blood glucose, lipid profile, uric acid, potassium,
calcium, creatinine, albumin, and urinary albumin-to-
creatinine ratio were determined by standard laboratory
methods.
Power Calculation
Considering 10 mm Hg and 10% as the standard
deviation of changes in systolic central arterial pressure
and AIx, respectively, a study with 20 patients in each
treatment arm would be required to detect a 9 mm Hg
or a 9% difference between central BP or AIx as being
significant with the conventional 5% a error and 80%
power. Assuming an approximately 20% dropout rate,
we planned to randomize 75 patients.
Data Analysis
Baselines. All analyses were performed using the per-
protocol sample. Baseline clinical, biochemical, and
hemodynamic data of the 3 patient groups were
compared by one-way analysis of variance (with Tukey
post hoc tests) for continuous and v2 tests for categor-
ical variables. Post hoc analyses for categorical variables
were done by univariate logistic regression with simple
contrasts.
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Changes Over Time. Mixed models with a random
intercept adjusted for baseline differences in covariates
were created to test for within-group changes over time
and also to test for between-group differences. The
Tables report baseline values for each group, within-
group changes over time, and the P value for the
heterogeneity of these between-group changes.
Additionally, in the case of AIx and backward-wave
amplitude, the above-described mixed models were
further adjusted for heart rate (centered at a rate of 75
per minute) and for a possible interaction of heart rate
and treatment assignment at the second investigation.
For graphical representation we calculated estimated
marginal means for each treatment group and time
point at a heart rate of 75 per minute.
Ancillary Analysis. To describe the association between
changes in heart rate and changes in the AIx, general
linear models were created with the change of AIx as the
outcome and treatment allocation and change in heart
rate as covariates including an interaction term into the
model. We tested whether the slopes were different from
zero and also whether slopes were different between
groups.
All analyses were performed by SPSS version 14.0
(SPSS, Inc, Chicago, IL). Data are presented as number
(percentage), meanstandard error, or 95% confidence
intervals. Two-sided P values <.05 were considered
statistically significant.
RESULTS
Participants and Recruitment
A flow diagram shows the progress and the number of
participants through the phases of the trial (Figure 1).
Eighty-four patients were screened for the study but 9
were not randomized because they did not meet the
inclusion criteria or declined to participate. Of the 75
patients randomized and allocated to intervention, 3
patients (2 metoprolol and 1 nebivolol) did not receive
the allocated intervention because they favored lifestyle
modification over drug treatment after the first hemo-
dynamic measurement. Seven patients were lost to
follow-up (3 metoprolol, 2 nebivolol, and 2 carvedilol),
as a result of traveling abroad or declining to return to
the second hemodynamic measurement. Five patients
discontinued medication because they experienced side
effects of dizziness, hypotension or toxicoderma (meto-
prolol), cold extremities (nebivolol), or erectile dysfunc-
tion (carvedilol). Among the 60 patients analyzed, 18
were randomized to metoprolol, 21 to nebivolol, and 21
to carvedilol. The rates of lost to follow-up were not
different between randomized treatment groups
(P=.23). Patients lost to follow-up had significantly
lower office diastolic BP (P=.02) and a smaller propor-
tion of current smokers (P=.03). Anthropometric data,
cardiovascular risk factors other than current smoking,
the use of antihypertensive drugs, and baseline hemo-
dynamic variables other than office diastolic BP were
Flow diagram
Enrollment Assessed for eligibility (n=84)
Excluded (n=9)
Not meeting inclusion criteria (n=4)
Declined to participate (n=5)
Randomized (n=75)
Allocated to intervention (n=26)
Received intervention (n=24)
Did not receive intervention (n=2)
Allocated to intervention (n=24)
Received intervention (n=24)
Did not receive intervention (n=0)
Allocated to intervention (n=25)
Received intervention (n=24)
Did not receive intervention (n=1)
Allocation
Follow-Up
Analysis
Lost to follow-up (n=3)
Discontinued medication (n=3)
Lost to follow-up (n=2)
Discontinued medication (n=1)
Lost to follow-up (n=2)
Discontinued medication (n=1)
Analyzed (n=18) Analyzed (n=21) Analyzed (n=21)
Metoprolol Nebivolol Carvedilol
FIGURE 1. Flow diagram representing the progress of the phases of the study.
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not different between patients analyzed or lost to
follow-up.
Baseline Characteristics of Participants
Anthropometric data, traditional cardiovascular risk
factors taken from case history, data regarding estab-
lished cardiovascular disease, diabetes, renal disease,
and use of current medication of the sample analyzed
(n=60) are summarized in Table I. Patients in the 3
treatment groups were of similar age, body mass index,
and waist circumference. Patients did not differ
regarding their smoking status, family history of car-
diovascular disease, and concomitant diseases. The use
of diuretics was more frequent among participants
receiving metoprolol compared with those receiving
nebivolol. Six patients in the metoprolol group, 6
patients in the nebivolol group, and 8 patients in the
carvedilol group required a dose increase during their
follow-up visit, respectively.
Brachial systolic, mean, and diastolic BPs decreased
significantly in all treatment groups, measured either as
office BP or as BP taken during hemodynamic data
collection. There was no between-group difference in
the degree of BP decrease. Confirming a decrease in BP,
24-hour BP monitoring was successful in 45 patients (16
in the metoprolol, 18 in the nebivolol, and 11 in the
carvedilol groups). In the carvedilol group, however
(probably because of the relatively low number of
patients), the drop in BP was not statistically significant
according to the ABPM measurements. As expected, all
drugs reduced heart rate to the same extent in each
treatment groups (Table II).
Primary Outcomes
Carotid systolic and diastolic BPs fell significantly in
each treatment groups, without any statistical difference
between the drugs. None of the drugs had any signif-
icant effect on AIx. AIx@75, however, was reduced by
5.42%2.5% (P=.034) in the nebivolol group.
Carvedilol and metoprolol did not change AIx@75
significantly (Table II and Figure 2).
Secondary Outcomes
Reflected wave amplitude remained unchanged in all
study groups. Reflected wave amplitude corrected for
heart rate of 75 per minute, however, decreased in the
carvedilol group (by 3.41.4 mm Hg, P=.02) and
showed a decreasing tendency in the nebivolol group
(by 2.01.0 mm Hg, P=.057), but no change was
observed in patients taking metoprolol (Figure 2).
Forward-traveling wave amplitude did not change
throughout the study. There was a significant interac-
tion between heart rate and taking carvedilol on
reflected wave amplitude (P=.026). Neither pulse
pressure amplification nor PWV changed significantly
throughout the study (Table II).
Ancillary Analyses
Determinants of changes in AIx were studied in simple
and multiple linear regression models. There was a
significant association between individual changes in
heart rate and changes in AIx within the carvedilol
group, but no such association was observed in the
metoprolol or nebivolol groups (P for heterogene-
ity=.03). The slope of the relationship in the nebivolol
group was significantly different from that in the
carvedilol (P=.01) or metoprolol (P=.048) groups.
(Figure 3).
Safety Measurements
Laboratory data collected at the onset and at the end of
the study are presented in Table III. Blood glucose, lipid
parameters, creatinine, electrolytes, uric acid, albumin,
TABLE I. Baseline Anthropometric Data,
Cardiovascular Risk Factors, Established Diseases,
and Current Medication of the 3 Treatment Arms
Studied
Metoprolol Nebivolol Carvedilol
P
Value
No. 18 21 21
Age, y 493 494 453 .63
Male/female 9/9 12/9 14/7 .57
BMI, kg/m2 29.61.0 28.10.7 29.00.8 .47
Waist circumference,
cm
1033 972 1003 .28
Current smoker 5 (28) 4 (19) 9 (43) .24
Past smoker 5 (28) 3 (14) 1 (5) .13
Family history of
cardiovascular
disease
7 (39) 4 (19) 8 (38) .30
Established
cardiovascular
disease
2 (11) 0 1 (5) .28
Diabetes 6 (33) 8 (38) 3 (14) .20
Renal disease 1 (6) 0 0 .31
Current medication
Treatment-na€ıve 3 (17) 9 (43) 9 (43) .15
ACE inhibitors 8 (44) 6 (29) 3 (14) .22
Angiotensin receptor
blockers
7 (39) 3 (14) 7 (33) .19
Calcium channel
blockers
7 (39) 6 (29) 6 (29) .93
Diuretics 12a (67) 3 (14) 8 (38) .04
a-Blockers 0 0 2 (9) .15
Statins 6 (33) 4 (19) 4 (19) .49
Oral antidiabetic
agents
6 (33) 5 (24) 3 (14) .37
Insulin 4 (22) 3 (14) 2 (9) .54
Abbreviations: ACE, angiotensin-converting enzyme; BMI, body mass
index. Data are meanstandard error of the mean for continuous
variables and number (percentages) for categorical variables. Estab-
lished cardiovascular disease and family history of cardiovascular
disease were defined as history of myocardial infarction, heart failure,
stroke, or peripheral arterial disease in the patient studied or in first-
degree relatives before the age of 55 years in men or 65 years in
women. aP<.05 vs nebivolol.
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FIGURE 2. Estimated augmentation index (AIx) and reflected wave amplitude centered at 75 beats per minute heart rate. Estimation was
based on mixed model analysis. Black columns represent baseline datastandard error of the mean and gray columns represent change from
baseline, with error bars indicating 95% confidence interval.
TABLE II. Brachial and Carotid Blood Pressures, Heart Rate, and Pulse Wave Velocity Before and After b-Blocker
Treatment
Metoprolol Nebivolol Carvedilol P Value
Office measurements
SBP, mm Hg 1503 1512 1471 .56
DSBP, mm Hg 22 (27 to 17) 21 (26 to 16) 14 (19 to 10)
DBP, mm Hg 923 882 922 .46
DDBP, mm Hg 15 (19 to 10) 12 (16 to 8) 11 (15 to 7)
Heart rate, beats per min 843 8210 848 .42
DHeart rate, beats per min 14 (18 to 10) 10 (14 to 6) 11 (14 to 7)
ABPM (n=45)
24 h SBP, mm Hg 1364 1393 1365 .40
D24-h SBP (mm Hg) 9 (16 to 2) 8 (15 to 2) 2 (10 to 6)
D24-h DBP, mm Hg 812 793 853 .15
D24-h DBP, mm Hg 8 (12 to 4) 7 (10 to 3) 2 (7 to 3)
Hemodynamic measurements
Heart rate, beats per min 742 742 773 .34
DHeart rate, beats per min 7 (11 to 3) 7 (11 to 3) 10 (14 to 7)
SBP brachial, mm Hg 1354 1423 1403 .27
DSBP brachial, mm Hg 7 (14 to 1) 14 (20 to 8) 9 (15 to 3)
DBP brachial, mm Hg 792 802 843 .48
DDBP brachial, mm Hg 7 (10 to 3) 8 (12 to 5) 5 (9 to 2)
SBP carotid, mm Hg 1213 1283 1243 .23
DSBP carotid, mm Hg 6 (11 to 1) 12 (16 to 7) 7 (11 to 2)
DBP carotid, mm Hg 802 802 843 .43
DDBP carotid, mm Hg 7 (10 to 3) 8 (12 to 5) 6 (9 to 2)
PWV, m/s 9.61.0 9.50.7 8.90.3 .92
DPWV, m/s 0.8 (2.4 to 0.7) 0.6 (2.1 to 0.8) 0.4 (1.8 to 1.0)
AIx, % 15.53.5 14.44.2 8.54.2 .47
DAIx, % 0.4 (4.7 to 5.4) 3.5 (8.2 to 1.2) 0.3 (5.0 to 4.4)
AP 1.330.02 1.330.03 1.410.03 .72
DAP 0.02 (0.08 to 0.04) 0.05 (0.10 to 0.005) 0.05 (0.11 to 0.002)
Pf, mm Hg 31.62.2 37.22.4 33.82.3 .95
DPf, mm Hg 0.7 (4.8 to 3.4) 1.4 (5.2 to 2.5) 1.5 (5.4 to 2.3)
Pb, mm Hg 17.61.1 20.11.2 18.01.3 .20
DPb, mm Hg 1.0 (1.0 to 3.0) 1.5 (3.3 to 0.4) 0.2 (2.1 to 1.6)
Abbreviations: ABPM, ambulatory blood pressure monitoring; AIx, augmentation index; AP, pulse pressure amplification; DBP, diastolic blood pressure;
Pb, reflected wave amplitude; Pf, forward travelling wave amplitude; PWV, pulse wave velocity; SBP, systolic blood pressure. Data are displayed as
baseline meanstandard error of the mean. Changes are displayed as change from baseline (95% confidence interval). P value represents the level of
difference between drug effect (P for heterogeneity).
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and urinary albumin-to-creatinine ratio did not differ
between treatment groups at either study visit. There
was a slight but statistically significant rise in plasma
potassium levels in patients taking carvedilol. Other
parameters measured did not change during the study.
DISCUSSION
The aim of the current clinical trial was to evaluate the
effect of 3-month treatment with metoprolol, nebivolol,
or low-dose carvedilol on central hemodynamics in
patients with uncontrolled hypertension. In the present
study, we found similar decreases of central BP irre-
spective of treatment arm, while no significant altera-
tions in AIx or PWV were found in either of the groups.
In contrast to no changes in the carvedilol and the
metoprolol groups, heart rate-adjusted AIx significantly
and reflected wave amplitude nonsignificantly decreased
in the nebivolol group. Individual changes in AIx within
the nebivolol-treated group seemed to be independent of
changes in heart rate. Carvedilol appears to have the
largest potential for decreasing reflected wave ampli-
tude; this effect, however, is strongly dependent on
current heart rate.
Our results are in agreement with those of previous
studies demonstrating similar decreases in central sys-
tolic pressure when comparing different b-blockers.7,8
We could not find any significant differences between
the central BP-lowering effects of carvedilol, nebivolol,
and metoprolol. We must acknowledge, however, that
nebivolol decreased central systolic pressure 6 mm Hg
more compared with metoprolol, which was not statis-
tically significant but may be considered biologically
significant. PWV did not decrease in any of the groups,
probably because of the relatively small decrease in BP
and the lack of a direct effect of the drugs on central
arteries. Indeed, whenever a fall in PWV during
b-blocker treatment was demonstrated, it seemed to be
the consequence of a larger drop in BP and not the
reduction of arterial stiffness.7,8
Tendencies in AIx changes seen in other studies7–9
suggested that the favorable hemodynamic effect of
nebivolol cannot be attributed exclusively to heart rate
reduction but could have arisen from its peripheral
vascular effects. By demonstrating the lack of a relation-
ship between the fall in AIx and heart rate reduction and a
tendency toward a decrease in reflected wave amplitude,
our study provides some direct evidence to this hypoth-
esis. A recent study of prehypertensive patients found a
significant increase in the production of endogenous
nitrovasodilator nitric oxide among nebivolol-treated
participants, assessed by urinary nitrate/nitrite excre-
tion.20 Although we did not perform a direct measure-
ment of nitric oxide production, such increment in nitric
oxide formation could contribute to the central hemody-
namic effects observed in the nebivolol arm.
As compared with nebivolol, the central hemody-
namic effects of the combined a- and b-blocker carv-
edilol are much less explored.10,11 In our study, no
changes were detected in the carvedilol group in AIx or
AIx@75; however, individual changes in heart rate and
AIx within the carvedilol group showed a negative
association. It seems, therefore, that a stronger
b-receptor antagonism and subsequent fall in heart
rate and rise in AIx may override the a-receptor
antagonism-associated peripheral vasodilation and fall
in AIx. One plausible explanation for this finding may
be the relatively low dose of carvedilol applied in
our study. Carvedilol demonstrates dose-dependent
FIGURE 3. Relationship between changes in heart rate (HR) and
changes in augmentation index (AIx) for metoprolol (upper panel),
nebivolol (middle panel), and carvedilol (lower panel).
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b-adrenoceptor antagonist activity from relatively low
doses, while it shows evidence of a-adrenoceptor
antagonist activity only at the dose of 25 mg,21 many
of our patients did not receive.
A recent study demonstrated that heart rate is an
important pressure-independent determinant of not only
AIx but of reflected wave amplitude as well.19 In the
carvedilol-treated group, adjustment of reflected wave
amplitude for heart rate revealed an interaction between
these parameters, indicating that at higher and lower
heart rates, carvedilol acts with different efficiency. At
higher heart rates, carvedilol profoundly decreases
reflected wave amplitude, while at lower heart rates, its
impact on reflected wave amplitude is minimal. Theo-
retically, the inverse of heart rate may be considered as an
index of sympathovagal balance.22 Higher heart rates
representing higher sympathetic outflow to the heart and
to vessels may provide an ideal setting for a-receptor
antagonism. Lower heart rates and lower sympathetic
outflow, however, may not yield much ground to the
a-receptor–associated effects of carvedilol.
The pharmacologic mechanism of action of carvedilol
is thought to be different from that of nebivolol. In
contrast to nebivolol, carvedilol-treated patients do not
exhibit an elevation in their plasma nitrate concentra-
tion but show an increase in their antioxidant
capacity.23
To our knowledge, no clinical study has aimed
to investigate the pharmacologic mechanisms,
hemodynamic effects, and clinical responses to both
newer b-blockers within the same study. Therefore, we
can only speculate that the similar beneficial cardiac
effects of nebivolol and carvedilol (eg, reduction of left
ventricular hypertrophy9,24) may represent similar
results related to different effects on central hemody-
namics.
Limitations
The current study involved only 60 patients and was
therefore relatively underpowered to detect subtle
changes in hemodynamic parameters or differences
between the 3 treatment arms. The 3-month duration
of the clinical trial was also relatively short, considering
that b-blocker effects may differ when studied over a
short- or long-term treatment period.9 It must also be
acknowledged that the dose of the drugs applied was
lower than recommended in large clinical trials or
national heart failure guidelines. However, we could
observe a significant reduction in heart rate even with
these relatively low doses, and the BP of our patients
with mild to moderate hypertension in the 3 treatment
groups decreased equally and to the normal range. A
recent study with carvedilol also suggested that even
daily doses >10 mg—the minimal dose that all of our
patients received—may have beneficial effects on
cardiovascular survival,25 indicating that clinically sig-
nificant hemodynamic effects may be observed well
below the maximal dose recommended. Because of the
TABLE III. Safety Parameters Before and 3 Months After b-Blocker Treatment
Metoprolol Nebivolol Carvedilol P Value
Glucose, mg/dL 11912 13615 1045 .45
DGlucose, mg/dL 1 (13 to 14) 6 (18 to 6) 5 (7 to 17)
Cholesterol, mg/dL 19211 1878 19111 .79
DCholesterol, mg/dL 1 (16 to 18) 7 (22 to 8) 5 (20 to 10)
Triglycerides, mg/dL 13719 17631 20952 .70
DTriglycerides, mg/dL 27 (64 to 119) 25 (104 to 55) 1 (81 to 82)
HDL cholesterol, mg/dL 524 535 492 .81
DHDL cholesterol, mg/dL 2 (6 to 2) 3 (7 to 0.4) 3 (7 to 1)
LDL cholesterol, mg/dL 1219 1158 12113 .90
DLDL cholesterol, mg/dL 1 (16 to 13) 5 (18 to 7) 5 (19 to 0)
Uric acid, mg/dL 5.90.4 5.30.3 5.80.3 .17
DUric acid, mg/dL 0.1 (0.7 to 0.5) 0.5 (0.1 to 1.1) 0.2 (0.8 to 0.4)
Creatinine, mg/dL 1.10.1 0.90.0 0.90.0 .09
DCreatinine, mg/dL 0.0 (0.09 to 0.01) 0.0 (0.01 to 0.07) 0.0 (0.06 to 0.03)
Potassium, mEq/L 4.40.1 4.50.1 4.20.1 .02
DPotassium, mEq/L 0.1 (0.2 to 0.1) 0.1 (0.2 to 0.1) 0.2 (0.1–0.4)
Calcium, mg/dL 9.50.2 9.40.1 9.30.1 .55
DCalcium, mg/dL 0.3 (0.2 to 0.8) 0.0 (0.5 to 0.4) 0.1 (0.3 to 0.6)
Albumin, g/dL 4.60.1 4.70.1 4.70.1 .91
DAlbumin, g/dL 0.1 (0.3 to 0.1) 0.1 (0.2 to 0.1) 0.1 (0.2 to 0.1)
UACR, mg/mmola 0.6 (0.31.4) 0.4 (0.22.2) 0.2 (0.10.8) .54
DUACR, mg/mmol 9.6 (19.9 to 0.7) 2.2 (12.2 to 7.8) 0.5 (9.4 to 10.3)
Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein; UACR, urinary albumin to creatinine ratio. Data are displayed as baseline
meanstandard error of the mean or in case of evidence against normal distribution amedian (interquartile range). Changes (D) are displayed as change
from baseline (95% confidence interval). P value represents the level of difference between drug effect (P for heterogeneity).
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inclusion of patients already treated with antihyperten-
sive drugs, we cannot exclude a potential confounding
effect due to unbalanced randomization. Nevertheless,
the frequency of the use of other drug classes—apart
from diuretics, a drug class with neutral or minimal
effect on central hemodynamics—did not differ between
the groups, so we hypothesize that this potential
confounding effect appeared equally in the 3 groups of
patients. The relatively large difference between
patients’ office BP and pressure taken during hemody-
namic measurements may suggest some misclassification
of patients as having uncontrolled hypertension during a
single screening visit. This difference, however, may
have also arisen from different conditions applied
during the 2 measurements. The nonblinded design
represents another limitation of the study.
CONCLUSIONS
In the current clinical trial we demonstrated that despite
the statistically indifferent effect on central arterial
pressure, nebivolol has a larger effect on AIx than
carvedilol or metoprolol. Our study expands earlier
observations by showing that the effects of nebivolol on
AIx are independent of the heart rate–decreasing effect
of the drug. The impact of carvedilol on AIx or reflected
wave amplitude, on the other hand, seems to exhibit
strong heart rate dependency. According to these
findings, b-blockers with vasodilatory effects cannot be
considered as a homogenous group regarding their
effects on central hemodynamics.
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